How Should We Determine the Role of Bezlotoxumab for Pediatric Clostridioides difficile Infection?

Journal of the Pediatric Infectious Diseases Society（2023）

引用 0|浏览1

暂无评分

摘要

The newly published MODIFY III trial established a safe pediatric dose of bezlotoxumab but did not conclusively demonstrate efficacy in decreasing the rate of recurrence of Clostridioides difficile infection in children. This editorial addresses considerations for bezlotoxumab use in pediatrics.

查看译文

关键词

Clostridioides difficile,bezlotoxumab,healthcare-associated infection,pediatrics,therapeutics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要